Tirofiban

DB00775

small molecule approved

Deskripsi

Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.

Struktur Molekul 2D

Berat 440.597
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2 hours
Volume Distribusi * 22 to 42 L
Klirens (Clearance) * 213 - 314 mL/min [Healthy subjects] * 152 - 267 mL/min [patients with coronary artery disease]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Metabolism appears to be limited.

Rute Eliminasi

It is cleared from the plasma largely by renal excretion, with about 65% of an administered dose appearing in urine and about 25% in feces, both largely as unchanged tirofiban.

Interaksi Obat

990 Data
Apixaban The risk or severity of adverse effects can be increased when Tirofiban is combined with Apixaban.
Dasatinib Dasatinib may increase the anticoagulant activities of Tirofiban.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Tirofiban is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Tirofiban is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Tirofiban.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan.
Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Tirofiban.
Obinutuzumab The risk or severity of adverse effects can be increased when Tirofiban is combined with Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Tirofiban.
Rivaroxaban Tirofiban may increase the anticoagulant activities of Rivaroxaban.
Tipranavir Tipranavir may increase the antiplatelet activities of Tirofiban.
Urokinase Tirofiban may increase the anticoagulant activities of Urokinase.
Vitamin E Vitamin E may increase the antiplatelet activities of Tirofiban.
Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Tirofiban.
Limaprost Limaprost may increase the antiplatelet activities of Tirofiban.
Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Tirofiban.
Tositumomab The risk or severity of adverse effects can be increased when Tirofiban is combined with Tositumomab.
Lepirudin The risk or severity of bleeding can be increased when Tirofiban is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding can be increased when Tirofiban is combined with Bivalirudin.
Alteplase The risk or severity of bleeding can be increased when Tirofiban is combined with Alteplase.
Reteplase The risk or severity of bleeding can be increased when Tirofiban is combined with Reteplase.
Anistreplase The risk or severity of bleeding can be increased when Tirofiban is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding can be increased when Tirofiban is combined with Tenecteplase.
Abciximab The risk or severity of bleeding can be increased when Tirofiban is combined with Abciximab.
Drotrecogin alfa The risk or severity of bleeding can be increased when Tirofiban is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding can be increased when Tirofiban is combined with Streptokinase.
Dicoumarol The risk or severity of bleeding can be increased when Tirofiban is combined with Dicoumarol.
Argatroban The risk or severity of bleeding can be increased when Tirofiban is combined with Argatroban.
Ardeparin The risk or severity of bleeding can be increased when Tirofiban is combined with Ardeparin.
Phenindione The risk or severity of bleeding can be increased when Tirofiban is combined with Phenindione.
Fondaparinux The risk or severity of bleeding can be increased when Tirofiban is combined with Fondaparinux.
Warfarin The risk or severity of bleeding can be increased when Tirofiban is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Tirofiban is combined with Phenprocoumon.
Dipyridamole The risk or severity of bleeding can be increased when Tirofiban is combined with Dipyridamole.
Heparin The risk or severity of bleeding can be increased when Tirofiban is combined with Heparin.
Enoxaparin The risk or severity of bleeding can be increased when Tirofiban is combined with Enoxaparin.
Epoprostenol The risk or severity of bleeding can be increased when Tirofiban is combined with Epoprostenol.
Acenocoumarol The risk or severity of bleeding can be increased when Tirofiban is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Tirofiban is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Tirofiban is combined with Coumarin.
Ximelagatran The risk or severity of bleeding can be increased when Tirofiban is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding can be increased when Tirofiban is combined with Desmoteplase.
Defibrotide The risk or severity of bleeding can be increased when Tirofiban is combined with Defibrotide.
Ancrod The risk or severity of bleeding can be increased when Tirofiban is combined with Ancrod.
Beraprost The risk or severity of bleeding can be increased when Tirofiban is combined with Beraprost.
Prasugrel The risk or severity of bleeding can be increased when Tirofiban is combined with Prasugrel.
Sulodexide The risk or severity of bleeding can be increased when Tirofiban is combined with Sulodexide.
Semuloparin The risk or severity of bleeding can be increased when Tirofiban is combined with Semuloparin.
Idraparinux The risk or severity of bleeding can be increased when Tirofiban is combined with Idraparinux.
Cangrelor The risk or severity of bleeding can be increased when Tirofiban is combined with Cangrelor.
Astaxanthin The risk or severity of bleeding can be increased when Tirofiban is combined with Astaxanthin.
Otamixaban The risk or severity of bleeding can be increased when Tirofiban is combined with Otamixaban.
Amediplase The risk or severity of bleeding can be increased when Tirofiban is combined with Amediplase.
Danaparoid The risk or severity of bleeding can be increased when Tirofiban is combined with Danaparoid.
Dalteparin The risk or severity of bleeding can be increased when Tirofiban is combined with Dalteparin.
Tinzaparin The risk or severity of bleeding can be increased when Tirofiban is combined with Tinzaparin.
(R)-warfarin The risk or severity of bleeding can be increased when Tirofiban is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Tirofiban is combined with Ethyl biscoumacetate.
Nadroparin The risk or severity of bleeding can be increased when Tirofiban is combined with Nadroparin.
Triflusal The risk or severity of bleeding can be increased when Tirofiban is combined with Triflusal.
Ticagrelor The risk or severity of bleeding can be increased when Tirofiban is combined with Ticagrelor.
Ditazole The risk or severity of bleeding can be increased when Tirofiban is combined with Ditazole.
Vorapaxar The risk or severity of bleeding can be increased when Tirofiban is combined with Vorapaxar.
Edoxaban The risk or severity of bleeding can be increased when Tirofiban is combined with Edoxaban.
Potassium citrate Potassium citrate may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.
Sodium citrate The risk or severity of bleeding can be increased when Tirofiban is combined with Sodium citrate.
Dextran The risk or severity of bleeding can be increased when Tirofiban is combined with Dextran.
Bemiparin The risk or severity of bleeding can be increased when Tirofiban is combined with Bemiparin.
Parnaparin The risk or severity of bleeding can be increased when Tirofiban is combined with Parnaparin.
Desirudin The risk or severity of bleeding can be increased when Tirofiban is combined with Desirudin.
Antithrombin Alfa The risk or severity of bleeding can be increased when Tirofiban is combined with Antithrombin Alfa.
Protein C The risk or severity of bleeding can be increased when Tirofiban is combined with Protein C.
Antithrombin III human The risk or severity of bleeding can be increased when Tirofiban is combined with Antithrombin III human.
Letaxaban The risk or severity of bleeding can be increased when Tirofiban is combined with Letaxaban.
Darexaban The risk or severity of bleeding can be increased when Tirofiban is combined with Darexaban.
Betrixaban The risk or severity of bleeding can be increased when Tirofiban is combined with Betrixaban.
Nafamostat The risk or severity of bleeding can be increased when Tirofiban is combined with Nafamostat.
Monteplase The risk or severity of bleeding can be increased when Tirofiban is combined with Monteplase.
Gabexate The risk or severity of bleeding can be increased when Tirofiban is combined with Gabexate.
Fluindione The risk or severity of bleeding can be increased when Tirofiban is combined with Fluindione.
Protein S human The risk or severity of bleeding can be increased when Tirofiban is combined with Protein S human.
Brinase The risk or severity of bleeding can be increased when Tirofiban is combined with Brinase.
Clorindione The risk or severity of bleeding can be increased when Tirofiban is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Tirofiban is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Tirofiban is combined with Tioclomarol.
Melagatran The risk or severity of bleeding can be increased when Tirofiban is combined with Melagatran.
Saruplase The risk or severity of bleeding can be increased when Tirofiban is combined with Saruplase.
(S)-Warfarin The risk or severity of bleeding can be increased when Tirofiban is combined with (S)-Warfarin.
Tocopherylquinone The risk or severity of bleeding can be increased when Tirofiban is combined with Tocopherylquinone.

Target Protein

Integrin alpha-IIb ITGA2B
Integrin beta-3 ITGB3

Referensi & Sumber

Synthesis reference: George Roby Thomas, Dawson James Reimer, Albert D. Friesen, "TRANSDERMAL PHARMACEUTICAL PREPARATION AND ADMINISTRATION OF TIROFIBAN." U.S. Patent US20120029447, issued February 02, 2012.

Contoh Produk & Brand

Produk: 14 • International brands: 2
Produk
  • Aggrastat
    Injection, solution • 5 mg/100mL • Intravenous • US • Approved
  • Aggrastat
    Injection, solution • 3.75 mg/15mL • Intravenous • US • Approved
  • Aggrastat
    Solution • 12.5 mg / 250 mL • Intravenous • Canada • Approved
  • Aggrastat
    Liquid • 0.25 mg / mL • Intravenous • Canada • Approved
  • Aggrastat
    Injection, solution • 5 mg/100mL • Intravenous • US • Approved
  • Aggrastat
    Injection, solution • 3.75 mg/15mL • Intravenous • US • Approved
  • Tirofiban
    Injection, solution • 5 mg/100mL • Intravenous • US • Generic • Approved
  • Tirofiban
    Injection, solution • 12.5 mg/250mL • Intravenous • US • Generic • Approved
Menampilkan 8 dari 14 produk.
International Brands
  • Aggribloc — Abbott
  • Agrastat — Merck Sharp & Dohme

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul